eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Portal dla gastroenterologów!
SCImago Journal & Country Rank
vol. 13
Poleć ten artykuł:
streszczenie artykułu:
Artykuł oryginalny

Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland

Paweł Kawalec, Ewa Stawowczyk

Data publikacji online: 2018/03/26
Pełna treść artykułu
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero

Ulcerative colitis (UC) is an idiopathic inflammatory bowel disorder, which requires lifelong treatment. It generates substantial direct and indirect costs, and significantly affects the quality of life, especially in the active state of the disease.

To evaluate the direct and indirect costs of UC as well as to assess disease activity and quality of life reported by patients with UC in Polish settings.

Material and methods
A questionnaire, cross-sectional study among UC patients as well as physicians involved in the therapy of the patients was conducted. The Clinical Activity Index (CAI) was used to assess disease activity, and the WPAI questionnaire to assess productivity loss. The quality of life was presented as utility calculated using the EQ-5D-3L questionnaire. Indirect costs included absenteeism, presenteeism, and informal care were assessed with the Human Capital Approach and expressed in euros (€). The productivity loss among informal caregivers was valuated with the average wage in Poland. Correlations were presented using the Spearman’s coefficient, and the between-group difference was assessed with Mann-Whitney U-test.

One hundred and forty-seven patients participated in the study, including 95 working persons. Mean cost of absenteeism and presenteeism was €1615.2 (95% CI: 669.5–2561.0) and €3684.4 (95% CI: 2367.8–5001.1), respectively, per year per patient with a disease in remission. The mean yearly cost of productivity loss due to informal care was estimated to be €256.6 (range: 0.0–532.6). The corresponding values for patients with active disease were: €8,913.3 (95% CI: 6223.3–11,603.3), €4325.1 (95% CI: 2282.4–6367.8), and €2396.1 (95% CI: 402.0–4390.3). The between-group difference in total indirect costs, cost of absenteeism, and cost of informal care was statistically significant (p < 0.05). The average weighted monthly costs of therapy with particular drugs categories (e.g. mesalazine or biologic drugs) differed significantly between active disease or remission patients. The difference in utility values between patients with a disease in remission (0.898 ±0.126) and patients with an active disease (0.646 ±0.302) was statistically significant.

Our study revealed the social burden of UC and high dependency of direct and indirect costs as well as quality of life on the severity of UC in Poland. The statistically significant differences were identified in total direct and indirect cost, cost of absenteeism, cost of informal care, and health-related quality of life among patients with an active disease compared to patients with a disease in remission.

Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-57.
Feagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802.
Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380: 1606-19.
Tontini GE, Vecchi M, Pastorelli L, et al. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol 2015; 21: 21-46.
Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics 2014; 32: 335-44.
Rachmilewitz D. Coated mesalazine versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 1989; 298: 82-6.
Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics 2014; 32: 335-44.
Golicki D, Jakubczyk M, Niewada M, et al. Valuation of EQ-5D health states in Poland: first TTO based social value set in Central and Eastern Europe. Value Health 2010; 13: 289-97.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
Central Statistical Office of Poland, http://stat.gov.pl/en/ Last Access: January 2016.
Havik K, Mc Morrow K, Orlandi F, et al. The production function methodology for calculating potential growth rates and output gaps. Economic Papers 535, November 2014, http://ec.europa.eu/economy_finance/publications/economic_paper/2014/pdf/ecp535_en.pdf.
Casellas F, Alcalá MJ, Prieto L, et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99: 457-61.
Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis 2014; 8: 598-606.
Mandel MD, Bálint A, Lovász BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014; 15 Suppl 1: S121-8.
Taleban S, Stewart KO, Li DK, et al. Clinical activity and quality of life indices are valid across ulcerative colitis but not Crohn’s disease phenotypes. Dig Dis Sci 2016; 61: 2627-35.
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe